SGEN

Seagen Stock Price

147.84
-1.51 (-1.01%)
147.84
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Seagen Inc SGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.51 -1.01% 147.84 08:17:16
Open Price Low Price High Price Close Price Prev Close
149.35
Bid Price Ask Price Spread News
143.06 148.46 5.40 - -
Trades Volume Avg Volume 52 Week Range
18 402 973,136 90.57 - 213.94
Last Trade Time Type Quantity Stock Price Currency
08:00:32 13 $ 150.00 USD

Seagen Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 26.46B 179.00M 60.40M $ 916.71M $ 260.07M -0.95 71.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Seagen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week152.21154.98141.50150.171,430,315-4.37-2.87%
1 Month180.00184.76141.50159.241,353,349-32.16-17.87%
3 Months193.31202.60141.50171.941,168,535-45.47-23.52%
6 Months146.43213.94141.50175.941,067,6151.410.96%
1 Year108.88213.9490.57160.691,101,33838.9635.78%
3 Years57.04213.9447.75108.541,000,70990.80159.19%
5 Years33.84213.9430.8487.37981,805114.00336.88%

Seagen Description

Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.


Your Recent History
NASDAQ
SGEN
Seagen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.